A study of danazol's safety

Area of Science:

• Pharmacovigilance
• Clinical Pharmacology
• Drug Safety Evaluation

Background:

• Danazol is a synthetic steroid derivative used in various medical conditions.
• Understanding the adverse event profile of danazol is crucial for patient safety.
• Previous studies have indicated potential side effects associated with danazol therapy.

Purpose of the Study:

• To determine the incidence and nature of adverse events following danazol administration.
• To assess the safety profile of danazol in a real-world clinical setting.
• To evaluate the occurrence of severe adverse events and long-term sequelae.

Main Methods:

• Retrospective review of medical records for 530 danazol recipients.
• Identification of adverse events reported within 45 days of drug administration.
• Analysis of event severity, need for hospitalization, and long-term outcomes.

Main Results:

• 154 out of 530 (29%) patients reported at least one adverse event.
• Adverse events occurred within 45 days post-danazol administration.
• No reported adverse events necessitated hospitalization.
• No known long-term sequelae were identified in any patient.

Conclusions:

• Danazol is associated with a 29% incidence of adverse events within 45 days.
• The observed adverse events were generally not severe, requiring no hospitalization.
• This study suggests a favorable safety profile regarding severe complications and long-term effects of danazol.